This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Look to REITs for 4% to 5% Yields in 2016 -- Strategist

Prices for real estate investment trusts sank in 2015. But one strategist foresees a good -- and stable -- year for REITs in 2016.

Sell Your Life Insurance Policy -- Don't Just Give It Up

Almost 88% of life insurance policies go unused or are surrendered. But consumers should know they have other options.

REIT Stocks Not Getting Enough Respect From Investors

REIT prices slowly sank over the course of 2015 as the market worried about the impact of potential Federal Reserve rate hikes.

Why Cashing Out Your Life Insurance Policy Could Be Your Best Move

Almost 88% of life insurance policies go unused or are surrendered and that could make cashing out of your policy the smartest move ever.

4 'Dirt Cheap' Stocks That Could Defy Market Drops

The wider market may be volatile, but David Bechtel of the Barrow Long/Short Opportunity Fund has four stock picks that could beat the odds.

Four Under The Radar Stocks to Own For The Long Term

The Barrow Long/Short Opportunity Fund's David Bechtel believes these four names could be great stocks to own for the long term.

Two ETF Plays for a Rebound in Biotech Stocks

The lack of major drug launches last year, along with disappointing quarterly results, dragged down biotech stocks last year. The downtrend has continued into 2016.

Buy Verizon, Walmart; Bow Out of Boeing, Citigroup

Shares of Boeing have dropped almost 17% so far in 2016 after a market-trouncing 11% return last year.

Fund Offers Strategic Protection in Wild Markets

Investors are only a month into a brand new year, yet already many are worn out from the market's mayhem.

Two ETFs to Play a Bounce Back in Biotech

The lack of major drug launches last year, along with disappointing quarterly results, dragged down biotech stocks last year but they could soon be headed higher.

Page 4 of 519
Top Rated Stocks Top Rated Funds Top Rated ETFs